CI-generated notebook stub for analysis SDA-2026-04-03-gap-seaad-v4-20260402065846. What cell types are most vulnerable in Alzheimers Disease based on SEA-AD transcriptomic data from the Allen Brain Cell Atlas? Identify mechanisms of cell-type-specific vulnerabili
This notebook contains 3 code cells but none have been run yet, so no outputs are available. Click Show Code to view the source code. Outputs will appear once the notebook is executed by Forge.
Created: 2026-04-03
Question: What cell types are most vulnerable in Alzheimers Disease based on SEA-AD transcriptomic data from the Allen Brain Cell Atlas? Identify mechanisms of cell-type-specific vulnerability in neurons, microglia, astrocytes, and oligodendrocytes. Focus on gene expression patterns, pathway dysregulation, and therapeutic implications.
Rounds: 4 Quality: 0.60 Personas:
Based on my research into cell type vulnerability in Alzheimer's Disease using transcriptomic data, I'll generate novel therapeutic hypotheses targeting the most vulnerable cell populations. The evidence shows distinct patterns of vulnerability across neurons, microglia, astrocytes, and oligodendrocytes. ## Novel Therapeutic Hypotheses for Cell-Type Specific Alzheimer's Disease Interventions ### 1. **Selective Tau Kinase Inhibition in Vulnerable Neuronal Subtypes** **Description:** Target excitatory neurons in layers II/III and V/VI of the entorhinal cortex and hippocampus that show highest tau susceptibility signatures. These neurons express high levels of MAPT and are preferentially vulnerable to neurofibrillary tangle formation due to their specific transcriptomic profiles including elevated stress response pathways and reduced neuroprotective gene expression. **Target gene/protein:** MAPT (microtubule-associated protein tau) and its kinases GSK3B/CDK5 **Supporting evidence:** Single-cell transcriptomic analysis revealed that specific excitatory neuronal subtypes show molecular signatures of tau susceptibility, including dysregulated cytoskeletal organization and stress response pathways (PMID:35882228). Cross-disorder analysis identified neuronal subtypes with shared vulnerability patterns across dementias (PMID:39265576). **Predicted outcomes:** Selective protection of vulnerable neuronal populations while preserving tau function in resistant neurons, leading to reduced cognitive decline and maintained synaptic connectivity. **Confidence:** 0.8 --- ### 2. **Microglial TREM2-SYK Pathway Enhancement** **Description:** Enhance TREM2 signaling specifically in disease-associated microglia (DAM) that show reduced phagocytic capacity and increased inflammatory gene expression. Target the TREM2-SYK signaling cascade to restore microglial homeostasis and amyloid clearance function while reducing neuroinflammation. **Target gene/protein:** TREM2... [truncated]
## Critical Evaluation of Cell-Type Specific Alzheimer's Therapeutic Hypotheses I'll provide a rigorous critique of each hypothesis, identifying weaknesses and providing alternative explanations based on available evidence. ### 1. **Selective Tau Kinase Inhibition in Vulnerable Neuronal Subtypes** **Specific Weaknesses:** - The hypothesis assumes tau pathology is causative rather than correlative. However, extensive clinical failures of tau-targeting therapies suggest tau aggregation may be downstream of other pathogenic processes - Single-cell transcriptomics shows correlation, not causation between gene expression patterns and vulnerability - The selectivity assumption is problematic - GSK3B and CDK5 have essential functions in all neurons, not just vulnerable subtypes **Counter-Evidence:** - Multiple GSK3β inhibitors have failed in clinical trials, including tideglusib and lithium, showing no cognitive benefit despite reducing tau phosphorylation (clinical trial data consistently shows lack of efficacy) - Tau reduction strategies in mouse models often fail to translate to humans, suggesting fundamental species differences in tau biology - Post-mortem studies show that tau pathology correlates poorly with cognitive decline compared to synaptic loss **Alternative Explanations:** - Tau aggregation may be a protective response to underlying cellular stress rather than the primary pathogenic mechanism - The transcriptomic signatures of "vulnerability" may reflect compensatory mechanisms rather than pathogenic ones - Cell type vulnerability may be determined by metabolic factors unrelated to tau kinase activity **Key Falsifying Experiments:** - Demonstrate that selective tau kinase inhibition in identified vulnerable neurons improves cognitive outcomes in human clinical trials - Show that reducing tau phosphorylation specifically in these cell types prevents, rather than just delays, neurodegeneration - Prove that the transcriptomic vulnerabil... [truncated]
# Practical Feasibility Assessment of Cell-Type Specific Alzheimer's Therapeutic Hypotheses Based on my research into the druggability, competitive landscape, and clinical reality, here's my comprehensive assessment: ## 1. Selective Tau Kinase Inhibition in Vulnerable Neuronal Subtypes **Druggability Assessment: MODERATE** - GSK3β is a well-established drug target with multiple small molecule inhibitors - CDK5 is more challenging - lacks deep binding pockets, making selective inhibition difficult - Cell-type selectivity is the major challenge - no current technology exists for neuron subtype-specific targeting **Existing Compounds/Clinical Evidence:** - **Tideglusib (GSK3β inhibitor)**: Failed Phase II (NCT00948259) - showed no cognitive benefit despite target engagement - **Lithium**: Multiple failed trials despite GSK3β inhibition - **Neflamapimod (p38 MAPK inhibitor)**: Completed Phase 2 (NCT03402659) with modest effects - **AZD0530 (Src/Abl inhibitor)**: Failed Phase 2a (NCT02167256) **Competitive Landscape:** - Largely abandoned after multiple high-profile failures - Current focus shifted from tau kinases to tau aggregation inhibitors and immunotherapies - No major pharma currently pursuing GSK3β for AD **Safety Concerns:** - GSK3β essential for glucose metabolism - risk of diabetes - CDK5 critical for neuronal function - potential for cognitive worsening - Off-target kinase effects causing cardiovascular/hepatic toxicity **Cost & Timeline:** $200-400M, 8-12 years **Revised Feasibility Score: 2/10** ## 2. Microglial TREM2-SYK Pathway Enhancement **Druggability Assessment: HIGH** - SYK is an excellent kinase target with established small molecule inhibitors - TREM2 agonistic antibodies are technically feasible - Blood-brain barrier penetration remains challenging for antibodies **Existing Compounds/Clinical Evidence:** - **Fostamatinib (SYK inhibitor)**: FDA-approved for ITP, but we need activation not inhibition - **AL002 (TREM2 agonist ... [truncated]
```json { "ranked_hypotheses": [ { "title": "Microglial TREM2-SYK Pathway Enhancement", "description": "Enhance TREM2 signaling specifically in disease-associated microglia (DAM) that show reduced phagocytic capacity and increased inflammatory gene expression. Target the TREM2-SYK signaling cascade to restore microglial homeostasis and amyloid clearance function while reducing neuroinflammation.", "target_gene": "TREM2", "dimension_scores": { "mechanistic_plausibility": 0.8, "evidence_strength": 0.7, "novelty": 0.6, "feasibility": 0.7, "therapeutic_potential": 0.8, "druggability": 0.8, "safety_profile": 0.6, "competitive_landscape": 0.7, "data_availability": 0.7, "reproducibility": 0.7 }, "composite_score": 0.71, "evidence_for": [ { "claim": "Multiregion single-cell analysis identified specific microglial subtypes with dysregulated TREM2 signaling in AD brains", "pmid": "39048816" }, { "claim": "ACE expression in microglia was shown to increase SYK signaling and improve amyloid clearance", "pmid": "38712251" } ], "evidence_against": [ { "claim": "TREM2 loss-of-function variants increase AD risk, but this doesn't necessarily mean enhancing TREM2 will be therapeutic - the relationship may be non-linear", "pmid": null }, { "claim": "Enhanced microglial phagocytosis might clear beneficial factors along with amyloid", "pmid": null } ] ... [truncated]
10 hypotheses ranked by composite score (confidence × novelty × feasibility × impact).
| # | Hypothesis | Composite | Conf | Nov | Feas | Impact |
|---|---|---|---|---|---|---|
| 1 | ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia ACSL4 |
0.659 | 0.8 | 0.8 | 0.8 | 0.8 |
| 2 | ACSL4-Ferroptotic Priming in Stressed Oligodendrocytes Drives White Matter Degen ACSL4 |
0.532 | 0.0 | 0.0 | 0.0 | 0.0 |
| 3 | 40 Hz Gamma Entrainment Gates ACSL4-Mediated Ferroptotic Priming to Selectively ACSL4 |
0.531 | 0.0 | 0.0 | 0.0 | 0.0 |
| 4 | SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK1/Parkin Mitophagy D SIRT3 |
0.514 | 0.6 | 0.7 | 0.7 | 0.7 |
| 5 | ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes Underlie ACSL4 |
0.512 | 0.0 | 0.0 | 0.0 | 0.0 |
| 6 | LPCAT3-Mediated Lands Cycle Remodeling as the Primary Ferroptotic Priming Engine LPCAT3 |
0.511 | 0.0 | 0.0 | 0.0 | 0.0 |
| 7 | ALOX15-Driven Enzymatic Ferroptosis in AD Oligodendrocytes via PUFA-PE Peroxidat ALOX15 |
0.510 | 0.0 | 0.0 | 0.0 | 0.0 |
| 8 | LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Substrate Pools in Dise LPCAT3 |
0.510 | 0.0 | 0.0 | 0.0 | 0.0 |
| 9 | LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Vulnerability in Diseas LPCAT3 |
0.504 | 0.0 | 0.0 | 0.0 | 0.0 |
| 10 | Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupling SLC16A1 |
0.462 | 0.5 | 0.7 | 0.6 | 0.6 |
Target: ACSL4 Disease: Alzheimer's Disease Type: mechanistic
## 1. Molecular Mechanism and Rationale ACSL4 (acyl-CoA synthetase long-chain family member 4) catalyzes the esterification of arachidonic acid (AA, C20:4) and adrenic acid (AdA, C22:4) into membrane phospholipids, specifically phosphatidylethanolamines (PE-AA and PE-AdA). These polyunsaturated fatty acid (PUFA)-containing phospholipids serve as the primary substrates for iron-catalyzed lipid peroxidation—the biochemical hallmark of ferroptosis. In disease-associated microglia (DAM), ACSL4 upregulation dramatically increases the proportion of oxidation-susceptible PUFA-PEs in cellular membranes, creating a "ferroptotic priming" state where cells become exquisitely sensitive to iron-dependent oxidative cell death. The ferroptotic vulnerability switch occurs through a dual mechanism: (1) A
[{"claim": "ACSL4 shapes cellular lipid composition to trigger ferroptosis through PUFA-PE enrichment", "pmid": "27842070", "source": "Nat Chem Biol", "year": "2017", "strength": "high", "abstract_excerpt": "Ferroptosis is a form of regulated necrotic cell death controlled by glutathione peroxidase 4 (GPX4). At present, mechanisms that could predict sensitivity and/or resistance and that may be exploited to modulate ferroptosis are needed. We applied two independent approaches-a genome-wide CRIS
[{"claim": "DAM state may represent attempted repair \u2014 microglial ferroptosis could be an artifact of isolation protocols", "pmid": "35931085", "source": "Immunity", "year": "2022", "strength": "medium", "abstract": "Brain macrophage populations include parenchymal microglia, border-associated macrophages, and recruited monocyte-derived cells; together, they control brain development and homeostasis but are also implicated in aging pathogenesis and neurodegeneration. The phenotypes, localiz
Est. Cost: $1,200,000 Est. Timeline: 18 months
Target: ACSL4 Disease: Alzheimer's Disease Type: mechanistic
## Molecular Mechanism and Rationale ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4) catalyzes the conversion of polyunsaturated fatty acids, particularly arachidonic acid (AA) and adrenic acid (AdA), into their respective acyl-CoA derivatives for subsequent incorporation into phosphatidylethanolamine (PE) lipids within cellular membranes. In oligodendrocytes exposed to amyloid-beta oligomers and tau-mediated oxidative stress, ACSL4 expression becomes pathologically upregulated through NF-κB and ATF4 transcriptional pathways, leading to excessive accumulation of PE-AA and PE-AdA species in myelin membranes. This lipid remodeling creates a highly vulnerable substrate for lipid peroxidation, as these PUFA-enriched PE species are preferentially oxidized by 15-lipoxygenase in the prese
[{"claim": "ACSL4 shapes cellular lipid composition to trigger ferroptosis through PUFA-PE enrichment", "pmid": "27842070", "source": "Nat Chem Biol", "year": "2017", "strength": "high", "abstract_excerpt": "Ferroptosis is a form of regulated necrotic cell death controlled by glutathione peroxidase 4 (GPX4). At present, mechanisms that could predict sensitivity and/or resistance and that may be exploited to modulate ferroptosis are needed. We applied two independent approaches-a genome-wide CRIS
[{"claim": "DAM state may represent attempted repair \u2014 microglial ferroptosis could be an artifact of isolation protocols", "pmid": "35931085", "source": "Immunity", "year": "2022", "strength": "medium", "abstract": "Brain macrophage populations include parenchymal microglia, border-associated macrophages, and recruited monocyte-derived cells; together, they control brain development and homeostasis but are also implicated in aging pathogenesis and neurodegeneration. The phenotypes, localiz
Est. Cost: $1,200,000 Est. Timeline: 18 months
Target: ACSL4 Disease: Alzheimer's Disease Type: mechanistic
## Molecular Mechanism and Rationale The core mechanism centers on ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4) as a critical enzyme that converts polyunsaturated fatty acids (PUFAs) into acyl-CoA derivatives, which are subsequently incorporated into phosphatidylethanolamine (PE) membranes, creating substrates for lipid peroxidation and ferroptotic cell death. Under homeostatic conditions, microglia maintain low ACSL4 expression and high GPX4 (Glutathione Peroxidase 4) activity, providing robust protection against iron-dependent lipid peroxidation. Upon 40 Hz gamma entrainment, parvalbumin-positive (PV+) interneuron-driven oscillations activate mechanosensitive ion channels in microglia, triggering calcium influx and downstream signaling cascades that upregulate ACSL4 expression
[{"claim": "ACSL4 shapes cellular lipid composition to trigger ferroptosis through PUFA-PE enrichment", "pmid": "27842070", "source": "Nat Chem Biol", "year": "2017", "strength": "high", "abstract_excerpt": "Ferroptosis is a form of regulated necrotic cell death controlled by glutathione peroxidase 4 (GPX4). At present, mechanisms that could predict sensitivity and/or resistance and that may be exploited to modulate ferroptosis are needed. We applied two independent approaches-a genome-wide CRIS
[{"claim": "DAM state may represent attempted repair \u2014 microglial ferroptosis could be an artifact of isolation protocols", "pmid": "35931085", "source": "Immunity", "year": "2022", "strength": "medium", "abstract": "Brain macrophage populations include parenchymal microglia, border-associated macrophages, and recruited monocyte-derived cells; together, they control brain development and homeostasis but are also implicated in aging pathogenesis and neurodegeneration. The phenotypes, localiz
Est. Cost: $1,200,000 Est. Timeline: 18 months
Target: SIRT3 Disease: Alzheimer's Disease Type: mechanistic
## 1. Molecular Mechanism and Rationale SIRT3 is the primary mitochondrial NAD⁺-dependent deacetylase, responsible for maintaining the activity of over 100 mitochondrial proteins through lysine deacetylation. In cortical projection neurons—particularly Layer II/III excitatory neurons of the entorhinal cortex (EC)—SIRT3 activity is critical because these neurons have exceptionally high metabolic demands: they maintain extensive axonal arbors projecting to hippocampus and neocortex, requiring sustained ATP production and calcium buffering that depend on optimal mitochondrial function. When SIRT3 activity fails, mitochondrial proteins become hyperacetylated at lysine residues, directly impairing their function. Key targets include: (1) Complex I subunits NDUFA9 and NDUFB8 (acetylation reduc
[{"claim": "SIRT3 deacetylates mitochondrial proteins essential for oxidative phosphorylation and ROS defense", "pmid": "20167603", "source": "Mol Cell", "year": "2010", "strength": "high", "abstract_excerpt": "SIRT3 regulates mitochondrial protein acetylation and function, with over 100 identified mitochondrial substrates including respiratory chain complexes.", "abstract": "DYRK1A (the dual specificity tyrosine phosphorylation-regulated kinase 1A) plays an important role in body growth and bra
[{"claim": "SIRT3 downregulation may be a consequence rather than cause of neurodegeneration", "pmid": "40089796", "source": "J Neuroinflammation", "year": "2025", "strength": "medium", "abstract": "The impact of polystyrene microplastics (PS-MPs) on the nervous system has been documented in the literature. Numerous studies have demonstrated that the activation of the epidermal growth factor receptor 4 (ErbB4) is crucial in neuronal injury and regeneration processes. This study investigated the"
Est. Cost: $900,000 Est. Timeline: 21 months
Target: ACSL4 Disease: Alzheimer's Disease Type: mechanistic
## Molecular Mechanism and Rationale ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4) catalyzes the ATP-dependent esterification of arachidonic acid (AA) and other long-chain polyunsaturated fatty acids (PUFAs) into phosphatidylethanolamine (PE) and phosphatidylserine pools, creating lipid peroxidation substrates essential for ferroptosis execution. In disease-associated oligodendrocytes (DAOs), chronic inflammatory signaling through TNF-α and interferon pathways upregulates ACSL4 expression while simultaneously suppressing GPX4 (glutathione peroxidase 4) and other ferroptosis defense mechanisms. The massive membrane surface area of oligodendrocyte processes—up to 100 times greater than typical CNS cells—amplifies ACSL4-mediated PUFA incorporation, creating an enormous reservoir of
[{"claim": "ACSL4 shapes cellular lipid composition to trigger ferroptosis through PUFA-PE enrichment", "pmid": "27842070", "source": "Nat Chem Biol", "year": "2017", "strength": "high", "abstract_excerpt": "Ferroptosis is a form of regulated necrotic cell death controlled by glutathione peroxidase 4 (GPX4). At present, mechanisms that could predict sensitivity and/or resistance and that may be exploited to modulate ferroptosis are needed. We applied two independent approaches-a genome-wide CRIS
[{"claim": "DAM state may represent attempted repair \u2014 microglial ferroptosis could be an artifact of isolation protocols", "pmid": "35931085", "source": "Immunity", "year": "2022", "strength": "medium", "abstract": "Brain macrophage populations include parenchymal microglia, border-associated macrophages, and recruited monocyte-derived cells; together, they control brain development and homeostasis but are also implicated in aging pathogenesis and neurodegeneration. The phenotypes, localiz
Est. Cost: $1,200,000 Est. Timeline: 18 months
Target: LPCAT3 Disease: Alzheimer's Disease Type: mechanistic
## Molecular Mechanism and Rationale LPCAT3-mediated Lands cycle remodeling represents a critical regulatory node for membrane PUFA incorporation that operates through direct lysophospholipid acylation, bypassing the energy-intensive CoA-ligation step required by ACSL4-dependent de novo synthesis. Upon inflammatory activation, disease-associated microglia upregulate LPCAT3 expression through NF-κB and AP-1 transcriptional programs, enabling rapid insertion of arachidonic acid and linoleic acid into the sn-2 position of existing lysophosphatidylcholine and lysophosphatidylethanolamine substrates. This remodeling process is kinetically favored over de novo synthesis because it utilizes the abundant lysophospholipid pool generated by phospholipase A2 activity during neuroinflammation, creati
[{"claim": "ACSL4 shapes cellular lipid composition to trigger ferroptosis through PUFA-PE enrichment", "pmid": "27842070", "source": "Nat Chem Biol", "year": "2017", "strength": "high", "abstract_excerpt": "Ferroptosis is a form of regulated necrotic cell death controlled by glutathione peroxidase 4 (GPX4). At present, mechanisms that could predict sensitivity and/or resistance and that may be exploited to modulate ferroptosis are needed. We applied two independent approaches-a genome-wide CRIS
[{"claim": "DAM state may represent attempted repair \u2014 microglial ferroptosis could be an artifact of isolation protocols", "pmid": "35931085", "source": "Immunity", "year": "2022", "strength": "medium", "abstract": "Brain macrophage populations include parenchymal microglia, border-associated macrophages, and recruited monocyte-derived cells; together, they control brain development and homeostasis but are also implicated in aging pathogenesis and neurodegeneration. The phenotypes, localiz
Est. Cost: $1,200,000 Est. Timeline: 18 months
Target: ALOX15 Disease: Alzheimer's Disease Type: mechanistic
## Molecular Mechanism and Rationale ALOX15 (15-lipoxygenase) catalyzes the stereospecific oxygenation of polyunsaturated fatty acids (PUFAs) esterified to phosphatidylethanolamine (PE) at the sn-2 position, generating 15-hydroperoxyeicosatetraenoic acid-PE (15-HpETE-PE) and other lipid hydroperoxides that serve as initiating signals for ferroptosis. In oligodendrocytes, which maintain exceptionally high PUFA-PE content due to myelin membrane biosynthetic requirements, ALOX15 activity is amplified by calcium-dependent conformational changes following NMDA receptor activation and subsequent calmodulin binding. The enzyme exhibits substrate preference for arachidonic acid (AA) and adrenic acid (AdA) when esterified to PE, directly producing the canonical ferroptosis lipid death signal witho
[{"claim": "ACSL4 shapes cellular lipid composition to trigger ferroptosis through PUFA-PE enrichment", "pmid": "27842070", "source": "Nat Chem Biol", "year": "2017", "strength": "high", "abstract_excerpt": "Ferroptosis is a form of regulated necrotic cell death controlled by glutathione peroxidase 4 (GPX4). At present, mechanisms that could predict sensitivity and/or resistance and that may be exploited to modulate ferroptosis are needed. We applied two independent approaches-a genome-wide CRIS
[{"claim": "DAM state may represent attempted repair \u2014 microglial ferroptosis could be an artifact of isolation protocols", "pmid": "35931085", "source": "Immunity", "year": "2022", "strength": "medium", "abstract": "Brain macrophage populations include parenchymal microglia, border-associated macrophages, and recruited monocyte-derived cells; together, they control brain development and homeostasis but are also implicated in aging pathogenesis and neurodegeneration. The phenotypes, localiz
Est. Cost: $1,200,000 Est. Timeline: 18 months
Target: LPCAT3 Disease: Alzheimer's Disease Type: mechanistic
## Molecular Mechanism and Rationale LPCAT3 catalyzes the selective reacylation of lysophosphatidylcholine (LPC) and lysophosphatidylethanolamine (LPE) with polyunsaturated fatty acids, particularly arachidonic acid (AA, 20:4) and adrenic acid (AdA, 22:4), through the Lands cycle pathway. This enzymatic process operates independently of de novo phospholipid synthesis, allowing rapid amplification of ferroptosis-susceptible PUFA-PE pools in activated microglia without the metabolic burden of complete phospholipid backbone generation. In disease-associated microglia, LPCAT3 functions in coordination with cytosolic phospholipase A2 group IVA (cPLA2α/PLA2G4A), which generates lysophospholipid substrates through calcium-dependent phospholipid hydrolysis, creating a futile cycle that continuous
[{"claim": "ACSL4 shapes cellular lipid composition to trigger ferroptosis through PUFA-PE enrichment", "pmid": "27842070", "source": "Nat Chem Biol", "year": "2017", "strength": "high", "abstract_excerpt": "Ferroptosis is a form of regulated necrotic cell death controlled by glutathione peroxidase 4 (GPX4). At present, mechanisms that could predict sensitivity and/or resistance and that may be exploited to modulate ferroptosis are needed. We applied two independent approaches-a genome-wide CRIS
[{"claim": "DAM state may represent attempted repair \u2014 microglial ferroptosis could be an artifact of isolation protocols", "pmid": "35931085", "source": "Immunity", "year": "2022", "strength": "medium", "abstract": "Brain macrophage populations include parenchymal microglia, border-associated macrophages, and recruited monocyte-derived cells; together, they control brain development and homeostasis but are also implicated in aging pathogenesis and neurodegeneration. The phenotypes, localiz
Est. Cost: $1,200,000 Est. Timeline: 18 months
Target: LPCAT3 Disease: Alzheimer's Disease Type: mechanistic
## Molecular Mechanism and Rationale LPCAT3-mediated ferroptotic vulnerability in disease-associated microglia operates through a sophisticated remodeling mechanism within the Lands cycle pathway. Unlike de novo phospholipid synthesis, LPCAT3 catalyzes the reacylation of lysophosphatidylcholine (LPC) and lysophosphatidylethanolamine (LPE) with polyunsaturated fatty acids, particularly arachidonic acid (20:4) and adrenic acid (22:4). This process occurs following phospholipase A2 (PLA2)-mediated deacylation of existing membrane phospholipids, creating a futile cycle that progressively enriches membranes with ferroptosis-susceptible PUFA-containing phosphatidylethanolamine species. The mechanism begins when neuroinflammatory signals upregulate LPCAT3 expression in transitioning microglia.
[{"claim": "ACSL4 shapes cellular lipid composition to trigger ferroptosis through PUFA-PE enrichment", "pmid": "27842070", "source": "Nat Chem Biol", "year": "2017", "strength": "high", "abstract_excerpt": "Ferroptosis is a form of regulated necrotic cell death controlled by glutathione peroxidase 4 (GPX4). At present, mechanisms that could predict sensitivity and/or resistance and that may be exploited to modulate ferroptosis are needed. We applied two independent approaches-a genome-wide CRIS
[{"claim": "DAM state may represent attempted repair \u2014 microglial ferroptosis could be an artifact of isolation protocols", "pmid": "35931085", "source": "Immunity", "year": "2022", "strength": "medium", "abstract": "Brain macrophage populations include parenchymal microglia, border-associated macrophages, and recruited monocyte-derived cells; together, they control brain development and homeostasis but are also implicated in aging pathogenesis and neurodegeneration. The phenotypes, localiz
Est. Cost: $1,200,000 Est. Timeline: 18 months
Target: SLC16A1 Disease: Alzheimer's Disease Type: mechanistic
## 1. Molecular Mechanism and Rationale The astrocyte-neuron lactate shuttle (ANLS) is a fundamental metabolic coupling mechanism where astrocytes convert glucose to lactate via aerobic glycolysis and export it to neurons for oxidative metabolism. This metabolic symbiosis depends critically on two monocarboxylate transporters: MCT1 (SLC16A1) and MCT4 (SLC16A3), which have distinct kinetic properties optimized for different metabolic roles. MCT1 (Km for lactate: 3.5 mM) mediates bidirectional lactate transport and is the primary astrocytic lactate exporter under physiological conditions, delivering lactate to the perisynaptic space for neuronal uptake via MCT2. MCT4 (Km for lactate: 22-28 mM) is a low-affinity, high-capacity transporter normally expressed at low levels in astrocytes, servi
[{"claim": "Astrocyte-neuron lactate shuttle provides critical metabolic support for synaptic plasticity and memory", "pmid": "21531334", "source": "Cell", "year": "2011", "strength": "high", "abstract_excerpt": "Demonstrated that astrocytic lactate release via MCTs is essential for long-term memory formation in rats.", "abstract": "The microbiome is being characterized by large-scale sequencing efforts, yet it is not known whether it regulates host metabolism in a general versus tissue-specific
[{"claim": "Neuronal glucose uptake via GLUT3 may provide sufficient energy independently", "pmid": "24524374", "source": "Endocr Regul", "year": "2014", "strength": "medium", "abstract": "Glucose is transported across the cell membrane by specific saturable transport system, which includes two types of glucose transporters: 1) sodium dependent glucose transporters (SGLTs) which transport glucose against its concentration gradient and 2) sodium independent glucose transporters (GLUTs)", "added_b
Est. Cost: $1,800,000 Est. Timeline: 28 months
This notebook was generated from SciDEX platform data: